EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Trifluridine/tipiracil and survival in mismatch repair-deficient metastatic colorectal cancer

Pei-Hung Chang iD, Wen-Kuan Huang, Yu-Li Su iD, Feng-Che Kuan, Jason Chia-Hsun Hsieh iD, Hung-Chih Hsu iD

Therapeutic Advances in Medical Oncology · 2026-06 · 18

DOI: 10.1177/17588359261458757 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Advances in Medical Oncology, online erschienen am 16.06.2026. Verfasst von Pei-Hung Chang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology-Oncology, Department of Internal Medicine, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Taiwan Association of Cancer Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

While trifluridine/tipiracil (FTD/TPI) is approved for refractory metastatic colorectal cancer (mCRC), its clinical benefit may vary based on molecular and clinical characteristics.

Objectives

To identify clinical and molecular factors associated with overall survival (OS) in patients with refractory mCRC treated with FTD/TPI.

Design

Retrospective, multicenter study.

Methods

A retrospective multicenter cohort study of 591 mCRC patients treated with FTD/TPI was conducted. Cox regression was used to identify independent prognostic factors for overall survival (OS).

Results

Median OS was 7.8 months in the overall cohort. Patients with deficient mismatch repair (dMMR) had significantly longer OS than those with proficient MMR ( p = 0.001). Body mass index (BMI) (hazard ratio (HR) = 0.96), neutrophil-to-lymphocyte ratio ⩾3 (HR = 1.94), and dMMR status (HR=0.29) were independent predictors of OS (all p < 0.001).

Conclusion

In this retrospective multicenter cohort, MMR status, BMI, and neutrophil-to-lymphocyte ratio (NLR) were identified as factors independently associated with OS among patients with refractory mCRC treated with FTD/TPI. These findings support the integration of molecular and clinical factors for prognostic stratification in later-line treatment settings

Schlagwörter

Stichwörter der Autor:innen

FTD/TPITAS-102metastatic colorectal cancermismatch repair deficiencyoverall survivaltrifluridine/tipiracil

Autor:innen und Institutionen

  • Division of Hematology-Oncology, Department of Internal Medicine, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan.
  • College of Medicine, Chang Gung University, Taoyuan, Taiwan.
  • Division of Hematology-Oncology, Department of Internal Medicine, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan.
  • Division of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
  • Division of Hematology-Oncology, Department of Internal Medicine, Chiayi Chang Gung Memorial Hospital, Chiayi, Taiwan.
  • Division of Hematology-Oncology, Department of Internal Medicine, Linkou Chang Gung Memorial Hospital, No. 5, Fu-Hsing Str., Guishan Dist., Taoyuan City, Taiwan 333423, Republic of China.

ORCID-Profile: Pei-Hung Chang, Yu-Li Su, Jason Chia-Hsun Hsieh, Hung-Chih Hsu

Förderung

  • Taiwan Association of Cancer Research

Zitieren

APA

Chang, P. H., Huang, W. K., Su, Y. L., Kuan, F. C., Hsieh, J. C., & Hsu, H. C. (2026). Trifluridine/tipiracil and survival in mismatch repair-deficient metastatic colorectal cancer. Therapeutic Advances in Medical Oncology, 18. https://doi.org/10.1177/17588359261458757

Vancouver

Chang PH, Huang WK, Su YL, Kuan FC, Hsieh JC, Hsu HC. Trifluridine/tipiracil and survival in mismatch repair-deficient metastatic colorectal cancer. Therapeutic Advances in Medical Oncology. 2026;18. doi:10.1177/17588359261458757

BibTeX
@article{Chang2026,
  author = {Chang, Pei-Hung and Huang, Wen-Kuan and Su, Yu-Li and Kuan, Feng-Che and Hsieh, Jason Chia-Hsun and Hsu, Hung-Chih},
  title = {Trifluridine/tipiracil and survival in mismatch repair-deficient metastatic colorectal cancer},
  journal = {Therapeutic Advances in Medical Oncology},
  year = {2026},
  volume = {18},
  doi = {10.1177/17588359261458757}
}
Kostenlos starten →